Brookfield and MidOcean make an $18bn Origin Energy bid; Shareholders & the board like it
Brookfield and Midocean have made another Origin Energy bid and this time it might be a case of third time lucky. Two earlier bids were met with the cold shoulder but after twice increasing the price, Origin Energy told shareholders it would back the bid if it became a formal, binding offer.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
The third Origin Energy bid this year
Since August, Origin Energy and its suitors have negotiated behind closed doors. The first bid was at $7.95 per share (inclusive of Origin’s H2 FY22 dividend) and the second was at $8.70-$8.90 per share.
This morning, the third Origin Energy bid was made public, coming in at $9 a share which values the company at $18.4bn. Origin shares rose by 34% to $7.84 at the market open, but falling short of the indicated offer.
The offer looks like it will go ahead
This Origin Energy bid is a 55% premium to yesterday’s closing price and unsurprisingly, Origin’s board told shareholders it would recommend shareholders accept the offer if it became a binding offer and in absence of a superior proposal.
If the Origin Energy bid is accepted goes ahead, the company would be split in two with MidOcean taking Australia Pacific LNG and Brookfield taking Origin’s core electricity and gas retailing and supply business. The share price rise this morning indicates that shareholders are optimistic that the deal will be completed.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.

Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now
FDA Approval Is a Big Win, Not the Finish Line Imricor Medical (ASX:IMR) received FDA clearance for its Vision-MR diagnostic…
How Nuclear Energy Became the World’s Most Feared Energy Source
Why Nuclear Energy Still Scares Us and What Really Went Wrong Many investors may remember periods when nuclear energy captured…
Dateline Resources (ASX:DTR) From 60c Highs to Hard Lessons
A Rare Earth Story the Market Loved Then Questioned For investors who have followed Dateline Resources (ASX:DTR), the past year…